For Professional Clients and, in Switzerland, for Qualified Investors only. In Israel for Sophisticated Investors only.
English
  • English
  • French
  • Spanish
en
  • en
  • fr
  • es
Filter by theme
Filter by date
Filter by boutique
Filter by theme
Filter by date
Filter by boutique
No posts matching your criteria
Clear theme
Clear all
No posts matching your criteria
Clear date
Clear all
No posts matching your criteria
Clear boutique
Clear all
For Professional Clients and, in Switzerland, for Qualified Investors only. In Israel for Sophisticated Investors only.
English
  • English
  • French
  • Spanish
en
  • en
  • fr
  • es
© 2019. BNY Mellon Investment Management International Limited. All rights reserved.
IDEAS AND KNOWLEDGE TO INSPIRE YOUR INVESTMENTS THINKING
18 September 2019

Will gene therapy deliver a healthcare revolution?

The advent of gene therapy could disrupt the healthcare industry as we know it, redefining the traditional avenues that pharmaceuticals and biotechnology make profits.

 

Over the past five years, biopharma’s approach to disease treatment has changed dramatically. Now, in the post human genome era, scientific advances have enabled us to develop techniques to target the root cause of disease – the genes that encode for these malfunctioning proteins. Collectively, we refer to these therapies as Gene Therapy (GTx). This technology is far more precise and powerful than in the past and, in some cases, it can offer close to curative treatments in a single dose.

 

While there has only been a few GTx approved by the US Food and Drug Administration (FDA) to date, the research into such therapies has rapidly expanded, as exemplified by the Investigational New Drug (IND) applications that are filed to test therapies in clinical trials. So far, most of these therapies target orphan monogenic diseases (diseases caused by a defect in a single gene). However, we believe that GTx will ultimately be used to treat far more prevalent conditions like heart failure, diabetes and even Alzheimer’s. The rapidly expanding addressable market, cutting-edge scientific techniques, and remarkable healthcare benefits GTx can provide make it a theme that we believe is ripe with potential opportunities.

 

Amanda Birdsey-Benson, PhD, Director, Senior Research Analyst, Mellon

Please note the content on this website is for Investment Professionals only and should be shared responsibly. No other persons should rely on the information contained within this website.

Investment Managers are appointed by BNY Mellon Investment Management EMEA Limited (BNYMIM EMEA) or affiliated fund operating companies to undertake portfolio management activities in relation to contracts for products and services entered into by clients with BNYMIM EMEA or the BNY Mellon funds.

 

Subscribe to updates